Immunotech Laboratories BG have begun negotiations in Macedonia and Serbia for Phase III testing on human patients

Immunotech Laboratories, Inc. (IMMB) and Immunotech Laboratories BG recently announced the successful completion of Phase I and Phase II field trials in Bulgaria of the Company’s HIV/AIDS and Hepatitis C virus treatment (“ITV-1 Treatment”) and have begun negotiations for sites in Macedonia and Serbia for Phase III testing on human…

Immunotech Laboratories, Inc. announced successful completion of Phase I and Phase II Field Trials in Bulgaria of the Company’s Patented Treatment of the HIV/AIDS and Hepatitis C Viruses

Immunotech Laboratories, Inc. (IMMB) announced today that the Phase I and Phase II field trials in Bulgaria of the Company’s HIV/AIDS and Hepatitis C virus treatment (“ITV-1 Treatment”) have been successfully completed. The clinical test are being conducted through Immunotech Laboratories, BG (“IMMB-BG”) a 49% owned subsidiary of Immunotech Laboratories….

Immunotech Laboraties, Inc. Retains The Lebrecht Group to Upgrade the Company to Fully Reporting Status

Immunotech Laboratories, Inc. (IMMB) today announced the company signed an agreement with The Lebrecht Group, a professional law corporation, to provide legal services for Immunotech and to upgrade the company to OTC:BB fully reporting current status. Immunotech Founder, President and Chief Science Officer Harry Zhabilov today commented, “This step will help assure…

Immunotech Laboratories Inc. Announces Breakthrough Results for HIV and AIDS Treatment for Terminal Salvage Patients

Immunotech Laboratories, Inc. (IMMB) Pursuant to significantly positive results with its patient population targeting full blown AIDS patients, the company has completed numerous clinical contracts with Mexican hospitals to initiate a full blown effort of clinical trial protocol preparation for its HIV/AIDS Vaccine drug candidate. The successful outcome of these…

Immunotech Laboratories, Inc. signed a contract with partner in Bulgaria to register a company called Immunotech Laboratories B.G. LLC

Immunotech Laboratories, Inc. (IMMB) signed a contract with strategic partners in Bulgaria to register a company called Immunotech Laboratories B.G. LLC. Immunotech Laboratories, Inc. will own 49% of the Bulgarian subsidiary. The goal of Immunotech Laboratories BG is to conduct pre-clinical testing, clinical trials phase I, phase II, and phase…

Immunotech Laboratories Agreement with Viral Genetics Inc.

In March 2012, Immunotech Laboratories, Inc. and collectively the Zhabilov Group, entered into a binding Release and Settlement Agreement with Viral Genetics Inc. and collectively the Viral Group and its principals that was approved by the court. The Settlement ends the almost 5-year-old lawsuit between the parties, dismissing all claims…

IPF – Scientific Abstract (presented on the 5th European Conference on Clinical And Social Research and AIDS and Drugs )

Below we show you the investigation that we presented on the 5th European Conference on Clinical And Social Research and AIDS and Drugs about IPF as a treatment for HIV.   IPF displays significant Antiviral activity in vitro without provoking the presentation of resistant profiles of minority subspecies Jeannie Gibbs,…